<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ESTRADIOL / NORETHINDRONE ACETATE - estradiol and norethindrone acetate tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Estradiol/Norethindrone Acetate Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"> 1.0 mg/0.5 mg<br> 0.5 mg/0.1 mg</p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">CARDIOVASCULAR AND OTHER RISKS</span></h1>
<p class="First">Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. (See <span class="Bold"><a href="#CS">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#W_Cardiovascular">WARNINGS, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a></span> and <span class="Bold"><a href="#W_Dementia"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a>.</span>)</p>
<p>The estrogen plus progestin substudy of the Women's Health Initiative (WHI) reported increased risks of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, invasive breast cancer, pulmonary emboli, and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) per day, relative to placebo. (See <span class="Bold"><a href="#CS">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#W_Cardiovascular">WARNINGS, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a></span> and <span class="Bold"><a href="#W_Malignant_Breast">Malignant neoplasms, Breast cancer</a>.</span>)</p>
<p>The estrogen-alone substudy of the WHI reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in postmenopausal women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively, of treatment with oral conjugated estrogens (CE 0.625 mg) per day, relative to placebo. (See <span class="Bold"><a href="#CS">CLINICAL STUDIES</a></span> and <span class="Bold"><a href="#W_Cardiovascular">WARNINGS, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a>.</span>)</p>
<p>The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI study, reported increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with CE 0.625 mg combined with MPA 2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See <span class="Bold"><a href="#CS">CLINICAL STUDIES</a>, <a href="#W_Dementia">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span> and <span class="Bold"><a href="#P_Geriatric">PRECAUTIONS, Geriatric Use</a>.</span>)</p>
<p>Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these trials, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin.</p>
<p>Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin.</p>
<p>Estradiol (E<span class="Sub">2</span>) is a white or almost white crystalline powder. Its chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol hemihydrate with the empirical formula of C<span class="Sub">18</span>H<span class="Sub">24</span>O<span class="Sub">2</span>, ½ H<span class="Sub">2</span>O and a molecular weight of 281.4. The structural formula of E<span class="Sub">2</span> is as follows:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-01.jpg"><p class="MultiMediaCaption">Estradiol</p>
</div>
<p>Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder. Its chemical name is 17β-acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one with the empirical formula of C<span class="Sub">22</span>H<span class="Sub">28</span>O<span class="Sub">3</span> and molecular weight of 340.5. The structural formula of NETA is as follows:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-02.jpg"><p class="MultiMediaCaption">Norethindrone Acetate</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
<p>Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system. Progestins produce similar endometrial changes to those of the naturally occurring hormone progesterone.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>PHARMACOKINETICS</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>A. Absorption</h3>
<p class="First">Estradiol is well absorbed through the gastrointestinal tract. Following oral administration of Estradiol/Norethindrone Acetate tablets, peak plasma estradiol concentrations are reached slowly within 5-8 hours. When given orally, estradiol is extensively metabolized (first-pass effect) to estrone sulfate, with smaller amounts of other conjugated and unconjugated estrogens. After oral administration, norethindrone acetate is rapidly absorbed and transformed to norethindrone. It undergoes first-pass metabolism in the liver and other enteric organs, and reaches a peak plasma concentration within 0.5 - 1.5 hours after the administration of Estradiol/Norethindrone Acetate tablets. The oral bioavailability of estradiol and norethindrone following administration of Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg when compared to a combination oral solution is 53% and 100%, respectively. Administration of Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg with food did not modify the bioavailability of estradiol, although increases in AUC<span class="Sub">0-72</span> of 19% and decreases in C<span class="Sub">max</span> of 36% for norethindrone were seen. The pharmacokinetic parameters of estradiol (E<span class="Sub">2</span>), estrone (E<span class="Sub">1</span>), and norethindrone (NET) following oral administration of 1 Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg or 2 Estradiol/Norethindrone Acetate 0.5 mg/0.1 mg tablet(s) to healthy postmenopausal women are summarized in Table 1.</p>
<a name="table1"></a><table width="90%">
<caption><span>TABLE 1 PHARMACOKINETIC PARAMETERS AFTER ADMINISTRATION OF 1 TABLET OF ESTRADIOL/NORETHINDRONE ACETATE 1.0 MG/0.5 MG OR 2 TABLETS OF ESTRADIOL/NORETHINDRONE ACETATE 0.5 MG/0.1 MG TO HEALTHY POSTMENOPAUSAL WOMEN</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="35%">
<col align="left" valign="top" width="35%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="left">1 × Estradiol/Norethindrone       Acetate Tablets</th>
<th align="left">2 × Estradiol/Norethindrone       Acetate Tablets</th>
</tr>
<tr>
<th align="left"></th>
<th align="left">1.0 mg/0.5 mg</th>
<th align="left">0.5 mg/0.1 mg</th>
</tr>
<tr>
<th align="left"></th>
<th align="left">(n=24)</th>
<th align="left">(n=24)</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="left">Mean<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>(%CV) <a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
<th align="left">Mean<a href="#footnote-1" class="Sup">*</a>(%CV) <a href="#footnote-2" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3">AUC = area under the curve, 0 – last quantifiable sample</td></tr>
<tr><td align="left" colspan="3">C <span class="Sub">max</span> = maximum plasma concentration,</td></tr>
<tr><td align="left" colspan="3">t<span class="Sub">max</span> = time at maximum plasma concentration,</td></tr>
<tr class="Last"><td align="left" colspan="3">t<span class="Sub">1/2</span> = half-life,</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>geometric mean;</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>geometric % coeffient of variation;</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>baseline unadjusted data;</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>baseline unadjusted data ;</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>n=13;</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Estradiol <a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>(E <span class="Sub">2</span>)</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  AUC <span class="Sub">0-t</span> (pg/mL*h)</td>
<td align="left">766.5 (48)</td>
<td align="left">697.3 (53)</td>
</tr>
<tr>
<td align="left">  C <span class="Sub">max</span> (pg/mL)</td>
<td align="left">26.8 (36)</td>
<td align="left">26.5 (37)</td>
</tr>
<tr>
<td align="left">  t <span class="Sub">max</span> (h): median (range)</td>
<td align="left">6.0 (0.5-16.0)</td>
<td align="left">6.5 (0.5-16.0)</td>
</tr>
<tr>
<td align="left">  t<span class="Sub">1/2</span> (h) <a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td align="left">14.0  (29)</td>
<td align="left">14.5  (27)</td>
</tr>
<tr>
<td align="left">Estrone <a href="#footnote-3" class="Sup">‡</a> (E <span class="Sub">1</span>)</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  AUC <span class="Sub">0-t</span>(pg/mL*h)</td>
<td align="left">4469.1 (48)</td>
<td align="left">4506.4 (44)</td>
</tr>
<tr>
<td align="left">  C <span class="Sub">max</span> (pg/mL)</td>
<td align="left">195.5 (37)</td>
<td align="left">199.5 (30)</td>
</tr>
<tr>
<td align="left">  t <span class="Sub">max</span> (h): median (range)</td>
<td align="left">6.0 (1.0-9.0)</td>
<td align="left">6.0 (2.0-9.0)</td>
</tr>
<tr>
<td align="left">  t <span class="Sub">1/2 </span>(h) <a href="#footnote-4" class="Sup">§</a>
</td>
<td align="left">10.7 (44) <a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td align="left">11.8 (25) <a href="#footnote-5" class="Sup">¶</a>
</td>
</tr>
<tr>
<td align="left">Norethindrone (NET)</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  AUC <span class="Sub">0-t</span> (pg/mL*h)</td>
<td align="left">21043 (41)</td>
<td align="left">8407.2 (43)</td>
</tr>
<tr>
<td align="left">  C <span class="Sub">max</span> (pg/mL)</td>
<td align="left">5249.5 (47)</td>
<td align="left">2375.4 (41)</td>
</tr>
<tr>
<td align="left">  t <span class="Sub">max</span> (h): median (range)</td>
<td align="left">0.7 (0.7-1.25)</td>
<td align="left">0.8 (0.7-1.3)</td>
</tr>
<tr class="Last">
<td align="left">  t <span class="Sub">1/2</span> (h)</td>
<td align="left"> 9.8 (32) 
                                       </td>
<td align="left">11.4 (36) 
                                       </td>
</tr>
</tbody>
</table>
<p>Following continuous dosing with once-daily administration of Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg, serum levels of estradiol, estrone, and norethindrone reached steady-state within two weeks with an accumulation of 33-47% above levels following single dose administration. Unadjusted circulating levels of E<span class="Sub">2</span>, E<span class="Sub">1</span>, and NET during Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg treatment at steady state (dosing at time 0) are provided in Figures 1a and 1b.</p>
<a name="i626e0e9f-3eee-4938-878b-16d109866d63"></a><table width="100%">
<caption><span>Figure 1a Levels of Estradiol and Estrone at Steady State During Continuous Dosing with Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg (n=24)</span></caption>
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center"><img alt="Figure 1a" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-03.jpg"></td></tr></tbody>
</table>
<a name="i6bafca9b-a18a-478d-8c97-0149141ed594"></a><table width="100%">
<caption><span>Figure 1b Levels of Norethindrone at Steady State During Continuous Dosing with Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg (n=24)</span></caption>
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center"><img alt="Figure 1b" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-04.jpg"></td></tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2"></a><p></p>
<h3>B. Distribution</h3>
<p class="First">The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estradiol circulates in the blood bound to sex-hormone-binding globulin (SHBG) (37%) and to albumin (61%), while only approximately 1-2% is unbound. Norethindrone also binds to a similar extent to SHBG (36%) and to albumin (61%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>C. Metabolism</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3.1"></a><p></p>
<h4>Estradiol</h4>
<p class="First">Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3.2"></a><p></p>
<h4>Norethindrone Acetate</h4>
<p class="First">The most important metabolites of norethindrone are isomers of 5α-dihydro-norethindrone and tetrahydro-norethindrone, which are excreted mainly in the urine as sulfate or glucuronide conjugates.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4"></a><p></p>
<h3>D. Excretion</h3>
<p class="First">Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. The half-life of estradiol following single dose administration of Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg is 12-14 hours. The terminal half-life of norethindrone is about 8-11 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.5"></a><p></p>
<h3>E. Special Populations</h3>
<p class="First">No pharmacokinetic studies were conducted in special populations, including patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.6"></a><p></p>
<h3>F. Drug Interactions</h3>
<p class="First">Coadministration of estradiol with norethindrone acetate did not elicit any apparent influence on the pharmacokinetics of norethindrone. Similarly, no relevant interaction of norethindrone on the pharmacokinetics of estradiol was found within the NETA dose range investigated in a single dose study.</p>
<p><span class="Italics">In-vitro</span> and <span class="Italics">in-vivo</span> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John's Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and result in side effects.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CS"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Effects on Vasomotor Symptoms</h2>
<p class="First">In a 12-week randomized clinical trial involving 92 subjects, Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg was compared to 1 mg of estradiol and to placebo. The mean number and intensity of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> were significantly reduced from baseline to week 4 and 12 in both the Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and the 1 mg estradiol group compared to placebo (see <a href="#figure2">Figure 2</a>).</p>
<a name="ia664c640-cbb0-49a6-86cb-6daaf67651ff"></a><table width="100%">
<caption><span>Figure 2 Mean Weekly Number of Moderate and Severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span> in a 12-Week Study</span></caption>
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center">
<a name="figure2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-05.jpg">
</td></tr></tbody>
</table>
<p>In a study conducted in Europe a total of 577 postmenopausal women were randomly assigned to either Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg, 0.5 mg E<span class="Sub">2</span>/0.25 mg NETA, or placebo for 24 weeks of treatment. The mean number and severity of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> were significantly reduced at week 4 and week 12 in the Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg (see <a href="#figure3">Figure 3</a>) and 0.5 mg E<span class="Sub">2</span>/0.25 mg NETA groups compared to placebo.</p>
<a name="i0cb72849-691c-4a21-817f-dd85c030adcf"></a><table width="100%">
<caption><span>Figure 3 Mean Number of Moderate to Severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span> for Weeks 0 Through 12</span></caption>
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center">
<a name="figure3"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-06.jpg">
</td></tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Effects on the Endometrium</h2>
<p class="First">Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg reduced the incidence of estrogen-induced <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> at 1 year in a randomized, controlled clinical trial. This trial enrolled 1,176 subjects who were randomized to one of 4 arms: 1 mg estradiol unopposed (n=296), 1 mg E<span class="Sub">2</span> + 0.1 mg NETA (n=294), 1 mg E<span class="Sub">2</span> + 0.25 mg NETA (n=291), and Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg (n=295). At the end of the study, endometrial biopsy results were available for 988 subjects. The results of the 1 mg estradiol unopposed arm compared to Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg are shown in Table 2.</p>
<a name="table2"></a><table width="100%">
<caption><span>TABLE 2 INCIDENCE OF <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">ENDOMETRIAL HYPERPLASIA</span> WITH UNOPPOSED ESTRADIOL AND ESTRADIOL/ NORETHINDRONE ACETATE TABLETS 1.0 MG/0.5 MG IN A 12-MONTH STUDY</span></caption>
<col align="left" valign="top" width="36%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">1 mg E <span class="Sub">2</span><br> (n=296)</th>
<th align="center">Estradiol/Norethindrone Acetate Tablets<br> 1 mg E<span class="Sub">2</span>/0.50mg NETA (n=295)</th>
<th align="center">1 mg E<span class="Sub">2</span>/0.25 mg NETA<br> (n=291 )</th>
<th align="center">1 mg E<span class="Sub">2</span>/0.1 mg<br> NETA (n=294 )</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">No. of subjects with histological evaluation at the end of the study</td>
<td align="center">247</td>
<td align="center">241</td>
<td align="center">251</td>
<td align="center">249</td>
</tr>
<tr>
<td align="left"><br></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">No. (%) of subjects with <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> at the end of the study</td>
<td align="center">36 (14.6%)</td>
<td align="center">1 (0.4%)</td>
<td align="center">1 (0.4%)</td>
<td align="center">2 (0.8%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2>Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting</h2>
<p class="First">During the initial months of therapy, irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting occurred with Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg treatment. However, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tended to decrease over time, and after 12 months of treatment with Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg, about 86% of women were amenorrheic (see <a href="#figure4">Figure 4</a>).</p>
<a name="i62594adf-11e6-488d-85b5-b25cc7d6f0b7"></a><table width="100%">
<caption><span>Figure 4 Patients Treated with Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg with Cumulative <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> over Time Percentage of Women with no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> or Spotting at any Cycle Through Cycle 13 Intent to Treat Population, LOCF</span></caption>
<col align="center" valign="top" width="100%">
<tfoot><tr class="First Last"><td align="left" colspan="1"><span class="Bold">Note: the percentage of patients who were amenorrheic in a given cycle and through cycle 13 is shown. If data were missing, the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> value from the last reported day was carried forward (LOCF).</span></td></tr></tfoot>
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center">
<a name="figure4"></a><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-07.jpg">
</td></tr></tbody>
</table>
<p>In the clinical trial with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg, 88% of women were amenorrheic after 6 months of treatment (see <a href="#figure5">Figure 5</a>).</p>
<a name="id8cf9778-3f67-491a-81d3-511c06065479"></a><table width="100%">
<caption><span>Figure 5 Patients Treated with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg with Cumulative <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> over Time Percentage of Women with no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> or Spotting at any Cycle Through Cycle 6, Intent to Treat Population, LOCF</span></caption>
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center">
<a name="figure5"></a><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-08.jpg">
</td></tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2>Effects on Bone Mineral Density</h2>
<p class="First">The results of two randomized, multicenter, calcium-supplemented (500-1000 mg/day), placebo-controlled, 2 year clinical trials have shown that Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and estradiol 0.5 mg are effective in preventing bone loss in postmenopausal women. While Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg was not directly studied in these trials, the US trial showed that addition of NETA to estradiol enhances the effect on BMD, therefore the BMD changes expected from treatment with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg should be at least as great as observed with estradiol 0.5 mg. A total of 462 postmenopausal women with intact uteri and baseline BMD values for lumbar spine within 2 standard deviations of the mean in healthy young women were enrolled. In a US trial, 327 postmenopausal women (mean time from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> 2.5 to 3.1 years) with a mean age of 53 years were randomized to 7 groups (0.25 mg, 0.5 mg, and 1 mg of estradiol alone, 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and 2 mg estradiol with 1 mg norethindrone acetate, and placebo.) In a European trial (EU trial), 135 postmenopausal women (mean time from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> 8.4 to 9.3 years) with a mean age of 58 years were randomized to 1 mg estradiol with 0.25 mg norethindrone acetate, 1 mg estradiol with 0.5 mg norethindrone acetate, and placebo. Approximately 58% and 67% of the randomized subjects in the two clinical trials, respectively, completed the two clinical trials. BMD was measured using dual-energy x-ray absorptiometry (DEXA).</p>
<p>A summary of the results comparing Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and estradiol 0.5 mg to placebo from the two prevention trials is shown in Table 3.</p>
<a name="table3"></a><table width="100%">
<caption><span>TABLE 3 PERCENTAGE CHANGE (MEAN ± SD) IN BONE MINERAL DENSITY (BMD) FOR ESTRADIOL/ NORETHINDRONE ACETATE TABLETS 1.0 MG/0.5 MG AND 0.5 MG E<span class="Sub">2 </span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> (Intent to Treat Analysis, Last Observation Carried Forward)</span></caption>
<col align="left" valign="top" width="21%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="17%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="3">US Trial</th>
<th align="center" colspan="2">EU Trial</th>
</tr>
<tr>
<th class="Rrule" align="left"></th>
<th align="center"></th>
<th align="center"></th>
<th class="Rrule" align="center">Estradiol/Norethindrone</th>
<th align="center"></th>
<th align="center">Estradiol/Norethindrone</th>
</tr>
<tr class="Last">
<th class="Rrule" align="left"></th>
<th align="center">Placebo <br>(n=37)</th>
<th align="center">0.5 mg E <span class="Sub">2</span><a href="#footnote-6" class="Sup">*</a><br>(n=31)</th>
<th class="Rrule" align="center">Acetate Tablets<br>1.0 mg/0.5 mg<br>(n=37)</th>
<th align="center">Placebo <br>(n=40)</th>
<th align="center">Acetate Tablets<br>1.0 mg/0.5 mg<br>(n=38)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">US= United States, EU = European</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>While Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg was not directly studied in these trials, the US trial showed that addition of NETA to estradiol enhances the effect on BMD, therefore the BMD changes expected from treatment with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg should be at least as great as observed with estradiol 0.5 mg.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Significantly (p&lt;0.001) different from placebo</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left">Lumbar spine</td>
<td align="center">-2.1 ± 2.9</td>
<td align="center">2.3 ± 2.8 <a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="center">3.8 ± 3.0 <a href="#footnote-7" class="Sup">†</a>
</td>
<td align="center">-0.9 ± 4.0</td>
<td align="center">5.4 ± 4.8 <a href="#footnote-7" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Rrule" align="left">Femoral neck</td>
<td align="center">-2.3 ± 3.4</td>
<td align="center">0.3 ± 2.9 
                                 </td>
<td class="Rrule" align="center">1.8 ± 4.1 <a href="#footnote-7" class="Sup">†</a>
</td>
<td align="center">-1.0 ± 4.6</td>
<td align="center">0.7 ± 6.1</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Femoral trochanter</td>
<td align="center">-2.0 ± 4.3</td>
<td align="center">1.7 ± 4.1 
                                 </td>
<td class="Rrule" align="center">3.7 ± 4.3 <a href="#footnote-7" class="Sup">†</a>
</td>
<td align="center">0.8 ± 6.9</td>
<td align="center">6.3 ± 7.6 <a href="#footnote-7" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
<p>The overall difference in mean percentage change in BMD at the lumbar spine in the US trial (1000 mg/day calcium) between Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and placebo was 5.9% and between estradiol 0.5 mg and placebo was 4.4%. In the European trial (500 mg/day calcium), the overall difference in mean percentage change in BMD at the lumbar spine was 6.3%. Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and estradiol 0.5 mg also increased BMD at the femoral neck and femoral trochanter compared to placebo. The increase in lumbar spine BMD in the US and European clinical trials for Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and estradiol 0.5 mg is displayed in Figure 6.</p>
<a name="i7b697387-fe94-4604-8aef-56c26d55cf08"></a><table width="100%">
<caption><span>Figure 6 Percentage Change in Bone Mineral Density (BMD) ± SEM of the Lumbar Spine (L1-L4) for Estradiol/Norethindrone Acetate Tablets 1.0 MG/0.5 MG and Estradiol 0.5 MG  (Intent to Treat Analysis with Last Observation Carried Forward)</span></caption>
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center">
<a name="figure6"></a><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=ena-09.jpg">
</td></tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2>Effect on Bone Turnover</h2>
<p class="First">Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg reduced serum and urine markers of bone turnover with a marked decrease in bone resorption markers (e.g., urinary pyridinoline crosslinks Type 1 collagen C- telopeptide, pyridinoline, deoxypyridinoline) and to a lesser extent in bone formation markers (e.g., serum osteocalcin, bone-specific alkaline phosphatase, C-terminal propetide of type 1 collagen). The suppression of bone turnover markers was evident by 3 months and persisted throughout the 24-month treatment period.</p>
<p>Treatment with 0.5 mg estradiol decreased biochemical markers of bone resorption (urinary pyridinoline, urinary deoxypyridinoline) and bone formation (bone-specific alkaline phosphatase) compared to placebo. These decreases occurred by 6 months of treatment after which the levels were maintained throughout the 24 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2>Women's Health Initiative Studies</h2>
<p class="First">The WHI enrolled a total of 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of either the use of oral conjugated estrogens (CE 0.625 mg per day) alone or the use of oral conjugated estrogens (CE 0.625 mg) plus medroxyprogesterone acetate (MPA 2.5 mg per day) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease (CHD) (nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome studied. A "global index" included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. The study did not evaluate the effects of CE or CE/MPA on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p>The estrogen-plus-progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.2 years of treatment, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the "global index." The absolute excess risk of events included in the "global index" was 19 per 10,000 women-years (RR 1.15, 95% nCI 1.03-1.28).</p>
<p>For those outcomes included in the WHI "global index," that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE/MPA were six more CHD events, seven more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, ten more PEs, and eight more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were seven fewer colorectal cancers and five fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. (See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a>, <a href="#WARNINGS">WARNINGS</a>,</span> and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>.)</p>
<p>Results of the estrogen-plus-progestin substudy, which included 16,608 women (average age of 63 years, range 50 to 79; 83.9 % White, 6.8 % Black, 5.4 % Hispanic, 3.9% Other) are presented in Table 4 below:</p>
<a name="table4"></a><table width="90%">
<caption><span>TABLE 4 RELATIVE AND ABSOLUTE RISK SEEN IN THE ESTROGEN-PLUS-PROGESTIN SUBSTUDY OF WHI AT AN AVERAGE OF 5.6 YEARS
                           </span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th align="left">Event</th>
<th align="center">Relative Risk<br>CE/MPA vs. Placebo<br>(95% nCI)</th>
<th align="center">CE/MPA<br>n = 8,506</th>
<th align="center">Placebo<br>n = 8,102</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center"></th>
<th align="center" colspan="2">Absolute Risk per 10,000 Women-years</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">CHD events</td>
<td align="center">1.24 (1.00-1.54)</td>
<td align="center">39</td>
<td align="center">33</td>
</tr>
<tr>
<td align="left"><span class="Italics">  Non-fatal MI</span></td>
<td align="center"><span class="Italics">1.28 (1.00-1.63)</span></td>
<td align="center"><span class="Italics">31</span></td>
<td align="center"><span class="Italics">25</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">  CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span></td>
<td align="center"><span class="Italics">1.10 (0.70-1.75)</span></td>
<td align="center"><span class="Italics">8</span></td>
<td align="center"><span class="Italics">8</span></td>
</tr>
<tr>
<td align="left">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></td>
<td align="center">1.31 (1.02–1.68)</td>
<td align="center">31</td>
<td align="center">24</td>
</tr>
<tr>
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></span></td>
<td align="center"><span class="Italics">1.44 (1.09–1.90)</span></td>
<td align="center"><span class="Italics">26</span></td>
<td align="center"><span class="Italics">18</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span></td>
<td align="center">1.95 (1.43–2.67)</td>
<td align="center">26</td>
<td align="center">13</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> </td>
<td align="center">2.13 (1.45–3.11)</td>
<td align="center">18</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">Invasive breast cancer
                                 </td>
<td align="center">1.24 (1.01–1.54)</td>
<td align="center">41</td>
<td align="center">33</td>
</tr>
<tr>
<td align="left">Invasive colorectal cancer</td>
<td align="center">0.56 (0.38–0.81)</td>
<td align="center">9</td>
<td align="center">16</td>
</tr>
<tr>
<td align="left">Endometrial cancer </td>
<td align="center">0.81 (0.48–1.36)</td>
<td align="center">6</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Cervical cancer </td>
<td align="center">1.44 (0.47–4.42)</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span> </td>
<td align="center">0.67 (0.47–0.96)</td>
<td align="center">11</td>
<td align="center">16</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span> </td>
<td align="center">0.65 (0.46–0.92)</td>
<td align="center">11</td>
<td align="center">17</td>
</tr>
<tr>
<td align="left">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> </td>
<td align="center">0.71 (0.59–0.85)</td>
<td align="center">44</td>
<td align="center">62</td>
</tr>
<tr class="Last">
<td align="left">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> </td>
<td align="center">0.76 (0.69–0.83)</td>
<td align="center">152</td>
<td align="center">199</td>
</tr>
</tbody>
</table>
<p>The estrogen-alone substudy was also stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen alone in predetermined primary endpoints. Results of the estrogen-alone substudy, which included 10,739 women (average age of 63 years, range 50 to 79; 75.3 % White, 15.1 % Black, 6.1 % Hispanic, 3.6% Other), after an average follow-up of 6.8 years are presented in Table 5 below.</p>
<a name="table5"></a><table width="90%">
<caption><span>TABLE 5 RELATIVE AND ABSOLUTE RISK SEEN IN THE ESTROGEN-ALONE SUBSTUDY OF WHI<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th align="center">Event</th>
<th align="center">Relative Risk <br>CE vs. Placebo</th>
<th align="center">CE <br>n = 5,310</th>
<th align="center">Placebo <br>n = 5,429</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center">(95% nCI<a href="#footnote-8" class="Sup">*</a>)</th>
<th align="center" colspan="2">Absolute Risk per 10,000 Women-years</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd>Results are based on an average follow-up of 6.8 years.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">§</a></dt>
<dd>Not included in Global Index.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">CHD events <a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</td>
<td align="center">0.95 (0.79–1.16)</td>
<td align="center">53</td>
<td align="center">56</td>
</tr>
<tr>
<td align="left"><span class="Italics">  Non-fatal MI<a href="#footnote-9" class="Sup">†</a></span></td>
<td align="center"><span class="Italics">0.91 (0.73–1.14)</span></td>
<td align="center"><span class="Italics">40</span></td>
<td align="center"><span class="Italics">43</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">  CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><a href="#footnote-9" class="Sup">†</a></span></td>
<td align="center"><span class="Italics">1.01(0.71–1.43)</span></td>
<td align="center"><span class="Italics">16</span></td>
<td align="center"><span class="Italics">16</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> <a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a>
</td>
<td align="center">1.39 (1.10-1.77)</td>
<td align="center">44</td>
<td align="center">32</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span> <a href="#footnote-9" class="Sup">†</a><span class="Sup">,</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">§</a>
</td>
<td align="center">1.47 (1.06–2.06)</td>
<td align="center">23</td>
<td align="center">15</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><a href="#footnote-9" class="Sup">†</a>
</td>
<td align="center">1.37 (0.90–2.07)</td>
<td align="center">14</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">  Invasive breast cancer<a href="#footnote-9" class="Sup">†</a>
</td>
<td align="center">0.80 (0.62–1.04)</td>
<td align="center">28</td>
<td align="center">34</td>
</tr>
<tr>
<td align="left">  Colorectal cancer <a href="#footnote-10" class="Sup">‡</a>
</td>
<td align="center">1.08 (0.75–1.55)</td>
<td align="center">17</td>
<td align="center">16</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span> <a href="#footnote-10" class="Sup">‡</a>
</td>
<td align="center">0.61 (0.41–0.91)</td>
<td align="center">11</td>
<td align="center">17</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span> <a href="#footnote-10" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-11" class="Sup">§</a>
</td>
<td align="center">0.62 (0.42-0.93)</td>
<td align="center">11</td>
<td align="center">17</td>
</tr>
<tr>
<td align="left">  Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> <a href="#footnote-10" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-11" class="Sup">§</a>
</td>
<td align="center">0.70 (0.63-0.79)</td>
<td align="center">139</td>
<td align="center">195</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes <a href="#footnote-10" class="Sup">‡</a><span class="Sup">,</span>
</td>
<td align="center">1.08 (0.88–1.32)</td>
<td align="center">53</td>
<td align="center">50</td>
</tr>
<tr>
<td align="left">  Overall mortality <a href="#footnote-10" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-11" class="Sup">§</a>
</td>
<td align="center">1.04 (0.88–1.22)</td>
<td align="center">81</td>
<td align="center">78</td>
</tr>
<tr class="Last">
<td align="left">  Global Index <a href="#footnote-10" class="Sup">‡</a><span class="Sup">,</span>
</td>
<td align="center">1.01 (0.91–1.12)</td>
<td align="center">192</td>
<td align="center">190</td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the WHI "global index" that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with estrogen-alone was 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while the absolute risk reduction per 10,000 women-years was six fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the "global index" was a nonsignificant two events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. (See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a>, <a href="#WARNINGS">WARNINGS</a>,</span> and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>.)</p>
<p>Final adjudicated results for CHD events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no overall difference for primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) in women receiving CE alone compared with placebo (see Table 5).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7"></a><p></p>
<h2>Women's Health Initiative Memory Study</h2>
<p class="First">The estrogen plus progestin Women's Health Initiative Memory Study (WHIMS) substudy of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 %, age 65 to 69 years, 35 %, age 70 to 74 years, 18 %, 75 years of age and older) to evaluate the effects of CE 0.625 mg plus MPA 2.5 mg daily on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of four years, 40 women in the estrogen-plus-progestin group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the hormone therapy group was 2.05 (95 % CI, 1.21-3.48) compared to placebo. It is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a>, </span><span class="Bold"><a href="#W_Dementia">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a>, </span> and <span class="Bold"><a href="#P_Geriatric">PRECAUTIONS, Geriatric Use</a></span>.)</p>
<p>The estrogen-alone WHIMS, a substudy of the WHI study, enrolled 2,947 predominantly healthy postmenopausal women 65 years of age and older (45 %, age 65 to 69 years, 36 %, age 70 to 74 years, 19 %, 75 years of age and older) to evaluate the effects of conjugated estrogens (CE 0.625 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 5.2 years, 28 women in the estrogen-alone group (37 per 10,000 women-years) and 19 in the placebo group (25 per 10,000 women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the estrogen-alone group was 1.49 (95% CI 0.83-2.66) compared to placebo.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95% CI 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a>, <a href="#W_Dementia">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a>, </span> and <span class="Bold"><a href="#P_Geriatric">PRECAUTIONS, Geriatric Use</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IU"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the:</p>
<ol class="Arabic">
<li>Treatment of moderate to severe vasomotor symptoms associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</li>
<li>Prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. When prescribing solely for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, therapy should only be considered for women at significant risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and non-estrogen medications should be carefully considered.</li>
</ol>
<p>The mainstays for decreasing the risk of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.</p>
<p>Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg is also indicated in women who have a uterus for the:</p>
<dl>
<dt>3. </dt>
<dd>Treatment of moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. When used solely for the treatment of symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, topical vaginal products should be considered.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Estradiol/Norethindrone Acetate Tablets should not be used in women with any of the following conditions:</p>
<ol>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>Known, suspected, or history of cancer of the breast.</li>
<li>Known or suspected estrogen-dependent neoplasia.</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, or history of these conditions.</li>
<li>Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>).</li>
<li>Liver dysfunction or disease.</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the ingredients of Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg or Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg.</li>
<li>Known or suspected pregnancy. There is no indication for Estradiol/Norethindrone Acetate Tablets in pregnancy. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. <span class="Bold">(See <a href="#PRECAUTIONS">PRECAUTIONS</a>.)</span>
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="W_Cardiovascular"></a><a name="section-7.1"></a><p></p>
<h2>1. <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></h2>
<p class="First">Estrogen-plus-progestin therapy has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> as well as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p>Estrogen-alone therapy has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT). Should any of these events occur or be suspected, estrogens should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (e.g., personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>a. <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></h3>
<p class="First">In the estrogen plus progestin substudy of the Women's Health Initiative (WHI), a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women receiving CE/MPA 0.625 mg/2.5 mg daily compared to women receiving placebo (31 vs. 24 per 10,000 women-years). The increase in risk was demonstrated after the first year and persisted. (See <span class="Bold"><a href="#CS">CLINICAL STUDIES</a></span>.)</p>
<p>In the estrogen-alone substudy of the WHI, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women receiving CE 0.625 mg daily compared to women receiving placebo (44 vs. 32 per 10,000 women-years). The increase in risk was demonstrated in year one and persisted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<h3>b. Coronary heart disease</h3>
<p class="First">In the estrogen-plus progestin sub-study of WHI, no statistically significant increase in CHD events (defined as non-fatal, MI, silent MI, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, due to CHD) was reported in women receiving CE/MPA compared to women receiving placebo (39 vs. 33 per 10,000 women years). An increase in relative risk was demonstrated in year one, and a trend toward decreasing relative risk was reported in years 2 through 5. (See <span class="Bold"><a href="#CS">CLINICAL STUDIES</a></span>.)</p>
<p>In the estrogen-alone substudy of WHI, no overall effect on <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary disease</span> (CHD) events was reported in women receiving estrogen alone compared to placebo. (See <span class="Bold"><a href="#CS">CLINICAL STUDIES</a></span>.)</p>
<p>In postmenopausal women with documented heart disease (n=2,763, average age 66.7 years), a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study (HERS)) treatment with CE/MPA (0.625mg/2.5mg per day) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE/MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE/MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Participation in an open-label extension of the original HERS trial (HERS II) was agreed to by 2,321 women. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE/MPA group and the placebo group in HERS, HERS II, and overall.</p>
<p>Large doses of estrogen (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risk of nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<h3>c. <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span></h3>
<p class="First">In the estrogen-plus-progestin substudy of the Women's Health Initiative (WHI), a statistically significant 2-fold greater rate of VTE (DVT and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> [PE]), was reported in women receiving CE/MPA compared to women receiving placebo (35 vs. 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 vs. 13 per 10,000 women-years) and PE (18 vs. 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted. (See <span class="Bold"><a href="#CS">CLINICAL STUDIES</a></span>.) In the estrogen-alone substudy of WHI, the risk of VTE was reported to be increased for women taking conjugated estrogens (30 vs. 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 vs. 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first two years.</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="W_Malignant"></a><a name="section-7.2"></a><p></p>
<h2>2. Malignant neoplasms</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="W_Malignant_Breast"></a><a name="section-7.2.1"></a><p></p>
<h3>a. Breast cancer</h3>
<p class="First">In some studies, the use of estrogens and progestins by postmenopausal women has been reported to increase the risk of breast cancer. The most important randomized clinical trial providing information about this issue is the CE/MPA substudy of the WHI study (see <span class="Bold"><a href="#CS">CLINICAL STUDIES</a></span>). The results from observational studies are generally consistent with those of the WHI clinical trial.</p>
<p>Observational studies have also reported an increased risk of breast cancer for estrogen-plus-progestin combination therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. For both findings, the excess risk increased with duration of use, and appeared to return to baseline over about five years after stopping treatment (only the observational studies have substantial data on risk after stopping). In these studies, the risk of breast cancer was greater, and became apparent earlier, with estrogen-plus-progestin combination therapy as compared to estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogens or among different estrogen-plus-progestin combinations, doses, or routes of administration.</p>
<p>In the estrogen-plus-progestin substudy, after a mean follow-up of 5.6 years, the WHI substudy reported an increased risk of breast cancer. In this substudy, prior use of estrogen alone or estrogen-plus-progestin combination hormone therapy was reported by 26% of the women. The relative risk of invasive breast cancer was 1.24 (95% nCI 1.01-1.54), and the absolute risk was 41 vs 33 cases per 10,000 women-years, for estrogen plus progestin compared with placebo, respectively. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 vs. 25 cases per 10,000 women-years, for estrogen plus progestin compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 vs. 36 cases per 10,000 women-years of estrogen plus progestin compared with placebo. In the WHI trial, invasive breast cancers were larger and diagnosed at a more advanced stage in the estrogen-plus-progestin group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups.</p>
<p>In the estrogen-alone substudy of WHI, after an average of 7.1 years of follow-up, CE (0.625 mg daily) was not associated with an increased risk of invasive breast cancer (RR 0.80, 95% nCI 0.62-1.04).</p>
<p>In a one-year trial among 1,176 women who received either unopposed 1 mg estradiol or a combination of 1 mg estradiol plus one of three different doses of NETA (0.1, 0.25, and 0.5 mg), seven new cases of breast cancer were diagnosed, two of which occurred among the group of 295 women treated with Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and two of which occurred among the group of 294 women treated with 1 mg estradiol/0.1 mg NETA.</p>
<p>The use of estrogen alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a health care provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<h3>b. Endometrial cancer</h3>
<p class="First">The use of unopposed estrogens in women with intact uteri has been associated with an increased risk of endometrial cancer. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12- fold greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than one year. The greatest risk appears associated with prolonged use, with an increased risk of 15- to 24-fold for five to ten years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women taking estrogen/progestin combinations is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
<p><span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> (a possible precursor of endometrial cancer) has been reported to occur in approximately 1% or less with Estradiol/Norethindrone Acetate Tablets in one large clinical trial.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="W_Dementia"></a><a name="section-7.3"></a><p></p>
<h2>3. <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the estrogen-plus-progestin Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, a population of 4,532 postmenopausal women aged 65 to 79 years was randomized to CE/MPA (0.625 mg/2.5 mg daily) or placebo. In the estrogen-alone WHIMS substudy, a population of 2,947 hysterectomized women, aged 65 to 79 years, was randomized to CE (0.625 mg daily) or placebo.</p>
<p>In the estrogen-plus-progestin substudy, after an average follow-up of four years, 40 women in the estrogen-plus-progestin group and 21 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for estrogen plus progestin vs. placebo was 2.05 (95% CI 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE/MPA vs. placebo was 45 vs. 22 cases per 10,000 women-years. In the estrogen-alone substudy, after an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE alone vs. placebo was 1.49 (95% CI 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE alone vs. placebo was 37 vs. 25 cases per 10,000 women-years.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95% CI 1.19-2.60). Since both substudies were conducted in women ages 65 to 79, it is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#P_Geriatric">PRECAUTIONS, Geriatric Use</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="W_Gallbladder"></a><a name="section-7.4"></a><p></p>
<h2>4. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></h2>
<p class="First">A two- to four- fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="W_Hypercalcemia"></a><a name="section-7.5"></a><p></p>
<h2>5. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in patients with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="W_Visual"></a><a name="section-7.6"></a><p></p>
<h2>6. Visual abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in patients receiving estrogens. Discontinue medication pending examination if there is a sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>A. General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<h3>1. Addition of a progestin when a woman has not had a hysterectomy.</h3>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone treatment. These include a possible increased risk of breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<h3>2. Elevated blood pressure</h3>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen. Blood pressure should be monitored at regular intervals with estrogen use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<h3>3. <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h3>
<p class="First">In patients with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and other complications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.4"></a><p></p>
<h3>4. <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired liver function</span> and past history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span></h3>
<p class="First">Estrogens may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.5"></a><p></p>
<h3>5. <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h3>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Patients with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Patients dependent on thyroid hormone replacement therapy who are also receiving estrogen may require increased doses of their thyroid replacement therapy. These patients should have their thyroid function monitored to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.6"></a><p></p>
<h3>6. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></h3>
<p class="First">Estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Because of this, patients who have conditions that might be influenced by this factor, such as a cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.7"></a><p></p>
<h3>7. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h3>
<p class="First">Estrogens should be used with caution in individuals with severe <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.8"></a><p></p>
<h3>8. Ovarian cancer</h3>
<p class="First">The estrogen-plus-progestin substudy of WHI reported that after an average follow-up of 5.6 years, the relative risk for ovarian cancer for estrogen plus progestin vs. placebo was 1.58 (95% CI 0.77 – 3.24), but was not statistically significant. The absolute risk for estrogen plus progestin vs. placebo was 4.2 vs. 2.7 cases per 10,000 women-years. In some epidemiologic studies, the use of estrogen-only products, in particular for 10 or more years, has been associated with an increased risk of ovarian cancer. Other epidemiologic studies have not found these associations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.9"></a><p></p>
<h3>9. Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> may be exacerbated with administration of estrogens.</p>
<p>Malignant transformation of residual endometrial implants has been reported in women treated post-hysterectomy with estrogen-alone therapy. For patients known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.10"></a><p></p>
<h3>10. Exacerbation of other conditions</h3>
<p class="First">Estrogens may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.2"></a><p></p>
<h2>B. Patient Information</h2>
<p class="First">Physicians are advised to discuss the contents of the Patient Information leaflet with patients for whom they prescribe Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg or Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8.3"></a><p></p>
<h2>C. Laboratory Tests</h2>
<p class="First">Estrogen administration should be initiated at the lowest dose approved for the indication and then guided by clinical response, rather than by serum hormone levels (e.g., estradiol, FSH).</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-8.4"></a><p></p>
<h2>D. Drug/laboratory Test Interactions</h2>
<ol class="Arabic">
<li>Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity, increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">Plasminogen</span> antigen and activity.</li>
<li>Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> levels (by column or by radioimmunoassay), or T<span class="Sub">3</span> levels by radioimmunoassay. T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> concent- rations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.</li>
<li>Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), SHBG) leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/rennin substrate, alpha-1 antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</li>
<li>Increased plasma HDL and HDL<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction concentration, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglyceride levels.</li>
<li>Impaired glucose tolerance.</li>
<li>Reduced response to metyrapone test.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.5"></a><p></p>
<h2>E. Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term continuous administration of estrogen, with or without progestin, in women with or without a uterus, has shown an increased risk of endometrial cancer, breast cancer, and ovarian cancer. (See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a>, <a href="#WARNINGS">WARNINGS</a>,</span> and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>.)</p>
<p>Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.6"></a><p></p>
<h2>F. Pregnancy</h2>
<p class="First">Estradiol/Norethindrone Acetate should not be used during pregnancy. (See <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.7"></a><p></p>
<h2>G. Nursing Mothers</h2>
<p class="First">Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of breast milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving this drug. Caution should be exercised when Estradiol/Norethindrone Acetate is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="P_Pediatric"></a><a name="section-8.8"></a><p></p>
<h2>H. Pediatric Use</h2>
<p class="First">Estradiol/Norethindrone Acetate Tablets are not indicated in children</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="P_Geriatric"></a><a name="section-8.9"></a><p></p>
<h2>I. Geriatric Use</h2>
<p class="First">Clinical studies of Estradiol/Norethindrone Acetate Tablets did not include sufficient number of subjects aged 65 and over to determine if they responded differently from younger subjects.</p>
<p>Of the total number of subjects in the estrogen-plus-progestin substudy of the Women's Health Initiative (WHI) study, 44% (n=7,320) were 65-74 years of age, while 6.6% (n=1,095) were 75 years and over. There was a higher relative risk (CE/MPA vs. placebo) of non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in women 75 and over compared to women less than 75 years of age. In women greater than 75, the increased risk of non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer observed in the estrogen-plus-progestin combination group compared to the placebo group was 75 vs. 24 per 10,000 women-years and 52 vs. 12 per 10,000 women-years, respectively.</p>
<p>In the estrogen-plus-progestin Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, a population of 4,532 hysterectomized women, aged 65 to 79 years, was randomized to CE/MPA (0.625 mg/2.5 mg daily) or placebo. In the estrogen-plus-progestin group, after an average follow-up of four years, the relative risk (CE/MPA vs. placebo) of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 2.05 (95% CI 1.21-3.48).The absolute risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> with CE/MPA was 45 vs. 22 cases per 10,000 women-years with placebo.</p>
<p>Of the total number of subjects in the estrogen-alone substudy of WHI, 46% (n=4,943) were 65 years and over, while 7.1% (n=767) were 75 years and over. There was a higher relative risk (CE vs. placebo) of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women less than 75 years of age compared to women 75 years and over. In the estrogen-alone WHIMS substudy, a population of 2,947 hysterectomized women, aged 65 to 79 years, was randomized to CE (0.625 mg daily) or placebo. After an average follow-up of 5.2 years, the relative risk (CE vs. placebo) of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.49 (95% CI 0.83-2.66). The absolute risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> with estrogen alone was 37 vs. 25 cases per 10,000 women-years with placebo.</p>
<p>Seventy-nine percent of the cases of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in women that were older than 70 for the CE-alone group, and 82 percent of the cases of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in women who were older than 70 in the CE/MPA group. The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the treatment groups and placebo groups was Alzheimer's disease.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95% CI 1.19-2.60). Since both substudies were conducted in women aged 65 to 79 years, it is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#W_Dementia">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a>, <a href="#WARNINGS">WARNINGS</a></span> and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<p>Adverse events reported with Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg by investigators in the Phase 3 studies regardless of causality assessment are shown in Table 6.</p>
<a name="table6"></a><table width="100%">
<caption><span>TABLE 6 ALL TREATMENT-EMERGENT ADVERSE EVENTS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF ≥ 5% WITH ESTRADIOL/NORETHINDRONE ACETATE TABLETS 1.0 MG/0.5 MG</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="2"><span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial Hyperplasia</span> Study <br>(12-Months)</th>
<th align="center" colspan="2">Vasomotor Symptoms Study <br>(3-Months)</th>
<th align="center" colspan="2"><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> Study <br>(2 years)</th>
</tr>
<tr>
<th align="left"></th>
<th align="center">Estradiol/Norethindrone Acetate Tablets<br>1.0 mg/0.5 mg</th>
<th align="center">1 mg E2</th>
<th align="center">Estradiol/Norethindrone Acetate Tablets<br>1.0 mg/0.5 mg</th>
<th align="center">Placebo</th>
<th align="center">Estradiol/Norethindrone Acetate Tablets<br>1.0 mg/0.5 mg</th>
<th align="center">Placebo</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center">(n=295)</th>
<th align="center">(n=296)</th>
<th align="center">(n=29)</th>
<th align="center">(n=34)</th>
<th align="center">(n=47)</th>
<th align="center">(n=48)</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>including one upper extremity <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in each group</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Bold Italics">Body as a Whole</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center">  6%</td>
<td align="center">  5%</td>
<td align="center">  3%</td>
<td align="center">  3%</td>
<td align="center">  6%</td>
<td align="center">  4%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">16%</td>
<td align="center">16%</td>
<td align="center">17%</td>
<td align="center">18%</td>
<td align="center">11%</td>
<td align="center">  6%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Digestive System</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">3%</td>
<td align="center">5%</td>
<td align="center">10%</td>
<td align="center">0%</td>
<td align="center">11%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">6%</td>
<td align="center">4%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Nervous System</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">6%</td>
<td align="center">4%</td>
<td align="center">3%</td>
<td align="center">3%</td>
<td align="center">0%</td>
<td align="center">8%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span></td>
<td align="center">1%</td>
<td align="center">1%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">6%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Respiratory System</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></td>
<td align="center">18%</td>
<td align="center">15%</td>
<td align="center">10%</td>
<td align="center">6%</td>
<td align="center">15%</td>
<td align="center">19%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">  7%</td>
<td align="center">11%</td>
<td align="center">  7%</td>
<td align="center">0%</td>
<td align="center">15%</td>
<td align="center">10%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Metabolic and Nutritional</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increase</span></td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">9%</td>
<td align="center">6%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Urogenital System</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span></td>
<td align="center">24%</td>
<td align="center">10%</td>
<td align="center">21%</td>
<td align="center">0%</td>
<td align="center">17%</td>
<td align="center">8%</td>
</tr>
<tr>
<td align="left">  Post-Menopausal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></td>
<td align="center">  5%</td>
<td align="center">15%</td>
<td align="center">10%</td>
<td align="center">3%</td>
<td align="center">11%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">Uterine Fibroid</span></td>
<td align="center">  5%</td>
<td align="center">  4%</td>
<td align="center">  0%</td>
<td align="center">0%</td>
<td align="center">4%</td>
<td align="center">8%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian Cyst</span></td>
<td align="center">  3%</td>
<td align="center">  2%</td>
<td align="center">  7%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">8%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Resistance mechanism</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection Viral</span></td>
<td align="center">4%</td>
<td align="center">6%</td>
<td align="center">0%</td>
<td align="center">3%</td>
<td align="center">6%</td>
<td align="center">6%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">Moniliasis Genital</span></td>
<td align="center">4%</td>
<td align="center">7%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">6%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Secondary Terms</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Injury Accidental</td>
<td align="center">4%</td>
<td align="center">3%</td>
<td align="center">3%</td>
<td align="center">0%</td>
<td align="center">17%<a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a>
</td>
<td align="center">4%<a href="#footnote-12" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td align="left">  Other Events</td>
<td align="center">2%</td>
<td align="center">3%</td>
<td align="center">3%</td>
<td align="center">0%</td>
<td align="center">6%</td>
<td align="center">4%</td>
</tr>
</tbody>
</table>
<p>Adverse events reported with Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg by investigators during the Phase 3 study regardless of causality assessment are shown in Table 7.</p>
<a name="table7"></a><table width="80%">
<caption><span>TABLE 7 ALL TREATMENT-EMERGENT ADVERSE EVENTS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF ≥ 5% WITH ESTRADIOL/NORETHINDRONE ACETATE TABLETS 0.5 MG/0.1 MG</span></caption>
<col align="left" valign="bottom" width="33%">
<col align="center" valign="bottom" width="34%">
<col align="center" valign="bottom" width="33%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">Estradiol/Norethindrone Acetate Tablets<br>0.5 mg/0.1 mg<br>(n=194)</th>
<th align="center">Placebo<br><br>(n=200)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Bold Italics">Body as a Whole</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center">10%</td>
<td align="center">  4%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">22%</td>
<td align="center">19%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td align="center">  5%</td>
<td align="center">  4%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Digestive System</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">  5%</td>
<td align="center">  4%</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">  6%</td>
<td align="center">  6%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Respiratory System</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center">21%</td>
<td align="center">18%</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Urogenital System</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Endometrial thickening</td>
<td align="center">10%</td>
<td align="center">  4%</td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal hemorrhage</span></td>
<td align="center">26%</td>
<td align="center">12%</td>
</tr>
</tbody>
</table>
<p>The following adverse reactions have been reported with estrogen and/or progestin therapy:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>1. Genitourinary system</h2>
<p class="First">Changes in <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> pattern and abnormal <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> or flow; breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; spotting; <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, increase in size of uterine leiomyomata; <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>; change in amount of cervical secretion; changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span>; pre-menstrual-like syndrome; <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>-like syndrome; ovarian cancer; <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>; endometrial cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>2. Breasts</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes; breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>3. Cardiovascular</h2>
<p class="First">Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; increase in blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>4. Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; changes in appetite; <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>; increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; enlargement of hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5"></a><p></p>
<h2>5. Skin</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span> that may persist when drug is discontinued; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>; hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>; loss of scalp hair; <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>; <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6"></a><p></p>
<h2>6. Eyes</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, intolerance to contact lenses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.7"></a><p></p>
<h2>7. Central nervous system</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>; <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; mood disturbances; <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>; exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>; probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8"></a><p></p>
<h2>8. Miscellaneous</h2>
<p class="First">Increase or decrease in weight; aggravation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; changes in libido; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; reduced carbohydrate tolerance; anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>; <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>; <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>; increased triglycerides; <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing drug products by young children. Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be re-evaluated periodically as clinically appropriate (e.g., 3 to 6 month intervals) to determine if treatment is still necessary (See <span class="Bold"><a href="#BOX">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>). For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<p>Estradiol/Norethindrone Acetate Tablets therapy consists of a single tablet to be taken once daily.</p>
<dl>
<dt>1.</dt>
<dd>For the treatment of moderate to severe vasomotor symptoms associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, and the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. When prescribing solely for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, therapy should only be considered for women at significant risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and non-estrogen medications should be carefully considered.<ul class="Disc">
<li>Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg</li>
<li>Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg</li>
</ul>
</dd>
<dt>2</dt>
<dd>For the treatment of moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>. When used solely for the treatment of symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, topical vaginal products should be considered.<ul class="Disc"><li>Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg</li></ul>
</dd>
</dl>
<p>Patients should be started at the lowest dose.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg</span> are white, convex, coated tablets debossed with "B" on one side and "474" on the other side (NDC 54868-4677-0).</p>
<p>Estradiol/Norethindrone Acetate Tablets are supplied as:    28 tablets in a calendar <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack dispenser.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Store in a dry place protected from light. Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature.]</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">WARNING: KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN. IN THE CASE OF ACCIDENTAL <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span> SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Distributed by:<br> Breckenridge Pharmaceutical, Inc.<br> Boca Raton, FL 33487</p>
<p>Manufactured by:<br> Pharmaceutics International, Inc.<br> Hunt Valley, Maryland 21031</p>
<p>ISSUED January 2010</p>
<br><p><br></p>
<p><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma        74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1.0 mg / 0.5 mg Carton</h1>
<p class="First"><img alt="PRINCIPAL DISPLAY PANEL - 1.0 mg / 0.5 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f&amp;name=4677.jpg"></p>
<p>NDC 54868-4677-0<br></p>
<p><span class="Bold">Estradiol / <br> Norethindrone Acetate Tablets</span></p>
<p><span class="Bold">1.0 mg / 0.5 mg</span></p>
<p><span class="Bold">28 tablets<br> Rx only</span></p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ESTRADIOL / NORETHINDRONE ACETATE 		
					</strong><br><span class="contentTableReg">estradiol and norethindrone acetate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4677(NDC:51991-474)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Estradiol</strong> (Estradiol) </td>
<td class="formItem">Estradiol</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Norethindrone Acetate</strong> (Norethindrone) </td>
<td class="formItem">Norethindrone Acetate</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>copovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round, convex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">B;474</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4677-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">28  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078324</td>
<td class="formItem">03/10/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-4677)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d59bd7ca-4da9-4f02-942a-d99066b741eb</div>
<div>Set id: b85df980-7df1-4973-bee3-ae51274b588f</div>
<div>Version: 1</div>
<div>Effective Time: 20120829</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
